Tiziana’s Phase 2 Alzheimer’s Trial Doses First Patient
Tiziana Life SciencesLife Sciences has dosed the first patient in a randomized, placebo-controlled Phase 2 study of intranasal foralumab...
From Full Outsourcing to CRO-Agnostic Oversight: How UCB Is Rethinking Operating Models Under R3
At the Veeva Clinical Oversight Forum in Copenhagen, we spoke with David Appel, CSM Team Lead at UCB, and...
What R3 Really Means for Outsourcing Decisions at Novo Nordisk
At the Veeva Clinical Oversight Forum in Copenhagen, we spoke with Ibrahim Kamstrup-Akkaoui, VP of Business Architecture and Partnerships...
A Vulnerable Infant Gut: The Critical Need for Restoration
Across multiple infant cohorts, up to 24% of U.S. infants had no detectable Bifidobacterium, with the absence rising to...
Immunovant Announces Pricing for Sizable $550M Stock Sale
Immunovant priced an underwritten public offering of 26.2 million primary shares at $21.00 per share for anticipated gross proceeds...
Cullgen’s Pain Drug CG001419 Shows Positive Phase 1 Results
Phase 1 data in 78 healthy volunteers showed CG001419 was well tolerated across single- and multiple-ascending doses with no...
Remarkable Lorundrostat Trial Noted by JAMA Research Roundup
Lorundrostat cut automated office systolic blood pressure by a mean 16.9 mmHg at Week 6 and 19.0 mmHg at...
FDA Approves Uplizna, A New Hope for Myasthenia Gravis
FDA has approved inebilizumab-cdon (Uplizna) for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive, based...
Tenaya’s Heart Gene Therapy Shows Promising Early Results
At the 3E13 vg/kg dose in Tenaya Therapeutics’ RIDGE-1 Phase 1b/2 study, three adults with PKP2-associated ARVC showed early...
First Patient Dosed in Tiziana’s Phase 2 Alzheimer’s Trial
TSPO-PET imaging in an Alzheimer’s patient already on lecanemab showed persistent, widespread microglial activation, underscoring residual neuroinflammation despite amyloid...